Contact information
Research groups
David Kerr
CBE FMedSci FRCP
Professor of Cancer Medicine
- Consultant Physician
Genetics and Genomics
In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.
Key publications
-
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article
Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557
Recent publications
-
A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study.
Journal article
Kleppe A. et al, (2022), Lancet Oncol
-
The UK benefits from a truly National Health Service.
Journal article
Barnes E. et al, (2022), Lancet
-
Cancer in sub-Saharan Africa: a Lancet Oncology Commission.
Journal article
Ngwa W. et al, (2022), Lancet Oncol
-
The Influence of Activin on the Tumor Microenvironment in Colon Cancer Metastasis.
Journal article
Wiley MB. et al, (2022), FASEB J, 36 Suppl 1
-
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
Journal article
Watts K. et al, (2022), Int J Cancer